Retatrutide Cost: Anticipated Pricing
The drug isn't approved, so no real price exists. Here's what to expect at launch based on how Lilly priced Mounjaro and Zepbound, with the caveat clearly attached to every number.
Retatrutide has no list price yet because it is not FDA-approved. Based on how Eli Lilly priced its previous GLP-1 launches, expect a list price of $1,000 to $1,200 per month at launch, a manufacturer cash-pay option starting around $400 to $600 per month at the lowest doses (similar to LillyDirect for Zepbound), and a savings card bringing commercial-insurance out-of-pocket cost to roughly $25 to $50 per month, with federal plans excluded as standard. These projections are scenarios, not commitments.
Lilly has not announced retatrutide pricing. The figures below are calibrated against how the company priced Mounjaro (2022) and Zepbound (2023). Treat them as planning ranges, not quotes. We will replace projections with actual numbers when Lilly publishes official pricing.
What we actually know
Retatrutide is in late Phase 3. Lilly has guided to NDA submission in 2026. Approval, if granted, would come 10 to 12 months after submission. Commercial launch typically follows within months of approval. So the earliest a retatrutide prescription could be filled at a U.S. pharmacy is late 2026, and more likely first half of 2027.
Until then, no NDC, no list price, no insurance contract, no pharmacy distribution. The price doesn't exist because the product doesn't exist for purchase.
Lilly's pricing pattern
Three Lilly GLP-1 launches in the last decade give us a reliable pattern:
| Drug | Launch year | Launch list price | Current cash-pay floor |
|---|---|---|---|
| Trulicity (dulaglutide) | 2014 | $730 | No cash-pay program |
| Mounjaro (tirzepatide, T2D) | 2022 | $1,023 | Savings Card to $25 |
| Zepbound (tirzepatide, obesity) | 2023 | $1,059 | $299–$449 |
| Retatrutide (projected) | 2026–2027 | $1,000–$1,200 | $400–$600 (initial) |
Sources: Lilly pricinginfo.lilly.com (current Zepbound pricing), historical SEC filings (launch list prices for Mounjaro and Trulicity), Lilly Q4 2023 earnings (Zepbound launch pricing).
Three scenarios for what you'll actually pay
Commercial insurance covers retatrutide
You have employer or marketplace insurance and your plan adds retatrutide to formulary. With a Lilly Savings Card, expect monthly out-of-pocket cost of $25 to $50. Plans typically require prior authorization for GLP-1 drugs (BMI threshold, prior weight-loss attempts, comorbidity documentation).
Cash-pay (uninsured or excluded plan)
Lilly will almost certainly launch a direct-to-consumer cash-pay option, mirroring LillyDirect for Zepbound. Initial pricing likely $400 to $600 per month for the lowest doses, with higher doses at the upper end of the range. Expect that floor to drop within 12 to 18 months as supply scales, repeating the Zepbound pattern.
Medicare or Medicaid
Medicare Part D coverage of GLP-1 drugs for obesity begins rolling out in July 2026. Retatrutide will likely qualify if approved by then. Under the Most-Favored-Nation pricing framework, expect Medicare copays capped around $50 per month for eligible enrollees. Medicaid coverage varies by state — about 13 states currently cover GLP-1s for obesity.
Expected savings card
Lilly has used a savings-card structure for every GLP-1 launch since Trulicity. The pattern: a $25-per-month commercial-insurance copay floor when the drug is on formulary, with a higher non-covered rate (around $650) for plans that exclude the drug but where the patient has commercial coverage. Federal plans are excluded by law from manufacturer copay cards.
We expect retatrutide to follow the same template. Card terms will be published at launch.
Expected self-pay path
Lilly opened a direct-to-consumer pharmacy (LillyDirect) for Zepbound in early 2024 and has been cutting cash-pay prices steadily since. The model has worked: it captured patients who would have otherwise sought compounded tirzepatide, and gave Lilly a margin floor above what generic competition would impose.
Expect a LillyDirect-equivalent for retatrutide at launch or within 6 months of launch. Initial single-dose-vial pricing likely $400 to $600 per month for the lowest titration doses, with multi-dose device pricing potentially lower (the new Zepbound Multi-Dose KwikPen brought higher-dose cash pricing below single-dose vial pricing).
Medicare and federal plans
Two policy frameworks materially affect retatrutide's expected federal-plan pricing:
- Medicare Part D obesity coverage (July 2026 rollout): Medicare historically excluded GLP-1 drugs prescribed for obesity (only diabetes-indicated use was covered). The November 2025 framework reverses that exclusion starting July 2026. Retatrutide, if approved by then, would be eligible.
- Most-Favored-Nation (MFN) pricing: the framework ties U.S. drug prices to the lowest prices paid in comparable countries. Implementation is still in progress. For Zepbound, the projected MFN price is approximately $346 per month on a government discount platform. Expect retatrutide to participate in MFN pricing if launched after the framework is operational.
Why compounded retatrutide doesn't exist
Compounding pharmacies in the U.S. operate under FDA rules that allow them to compound drugs from three categories: bulk substances on the FDA's approved compounding list, drugs in active shortage, and approved drug active ingredients combined for patient-specific clinical needs. Retatrutide doesn't fit any of these categories. It's an unapproved investigational molecule.
What does exist online: vials labeled “research use only” sold by sites that explicitly disclaim human use. The active ingredient is not pharmaceutical-grade, the concentration is not verified by any regulator, and the supply chain is not subject to any quality control. These products are not safe to inject regardless of price.
For compounded tirzepatide, some prescribers argue that compounding allows micro-dosing flexibility that the branded weekly pen does not. That argument requires an FDA-approved on-label dose to titrate against. Retatrutide has no FDA-approved on-label dose. There is no clinical anchor for what a “low” or “flexible” retatrutide dose even is.
Frequently asked
Retatrutide is not FDA-approved. Every claim on this page is sourced to one of: peer-reviewed publication (Phase 2 results in NEJM), ClinicalTrials.gov registry data (Phase 3 design and status), Lilly investor and pipeline disclosures (timeline guidance), or clearly labeled projection (anticipated pricing). We do not publish dosing instructions for unapproved drugs. We do not link to research-use-only suppliers. Medical content reviewed by Dr. Golsa Gholampour, MD, board-certified in obesity medicine. Page re-verified monthly until FDA submission status changes.